Cotellic

Active Ingredient(s): Cobimetinib
FDA Approved: * November 10, 2015
Pharm Company: * GENENTECH INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Cotellic Overview

Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech (Roche). It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf). Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.[4] Cobimetinib in ...

Read more Cotellic Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cobimetinib

Recent Cotellic Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Cobimetinib

Tablet: 20mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Cotellic: (1 result)

Sorted by National Drug Code

50242-717 Cotellic 20 mg Oral Tablet, Film Coated by Genentech, Inc.

Other drugs which contain Cobimetinib or a similar ingredient: (1 result)

COBIMETINIB